What’s happening: Johnson & Johnson will stop its plan that would have required hospitals participating in the 340B drug discount program to purchase Stelara and Xarelto at full price and apply for a rebate instead of receiving full discounts upfront.
What else to know: The Health Resources and Services Administration (HRSA) notified J&J it would be kicked out of the 340B Drug Pricing Program if it did not halt implementation.
On Sept. 19, CHA sent a letter to U.S. Department of Health & Human Services (HHS) Secretary Xavier Becerra and HRSA Administrator Carole Johnson in support of the HRSA’s position.
On Sept. 27, Reps. Doris Matsui (D-CA), Dusty Johnson (R-SD), Abigail Spanberger (D-VA), Tracey Mann (R-KS), Debbie Dingell (D-MI), and Rob Wittman (R-VA) sent a letter to HHS Secretary Becerra urging the department to take action against J&J if it did not abandon its proposal.
The letter had 189 signatures, including 30 members of the California congressional delegation:
- Barragán (D-CA-44)
- Bera (D-CA-6)
- Brownley (D-CA-26)
- Carbajal (D-CA-24)
- Cárdenas (D-CA-29)
- Chu (D-CA-28)
- Costa (D-CA-21)
- DeSaulnier (D-CA-10)
- Eshoo (D-CA-16)
- Fong (R-CA-20)
- Garamendi (D-CA-8)
- Garcia, Mike (R-CA-27)
- Garcia, Robert (D-CA-42)
- Gomez, Jimmy (D-CA-34)
- Harder (D-CA-9)
- Kamlager-Dove (D-CA-37)
- Khanna (D-CA-17)
- Lee (D-CA-12)
- Lieu (D-CA-36)
- Lofgren (D-CA-18)
- Matsui (D-CA-7), lead author
- Napolitano (D-CA-31)
- Panetta (D-CA-19)
- Porter (D-CA-47)
- Schiff (D-CA-30)
- Takano (D-CA-39)
- Thompson (D-CA-4)
- Valadao (R-CA-22)
- Vargas (D-CA-52)
- Waters (D-CA-43)
